专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US07615214B2 Anti-human VEGF receptor Flt-1 monoclonal antibody 有权
标题翻译：抗人VEGF受体Flt-1单克隆抗体
公开(公告)号：US07615214B2
公开(公告)日：2009-11-10
申请号：US11250411
申请日：2005-10-17
申请人： Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi Shibuya
发明人： Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi Shibuya
IPC分类号： A61K39/395 , C07K16/00 , C07K16/28
CPC分类号： G01N33/57407 , A61K38/00 , C07K16/2803 , C07K16/2863 , C07K2317/24 , C12N2799/026 , G01N33/6863 , G01N33/6893 , G01N33/74
摘要： The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.
摘要翻译：本发明提供了与人VEGF受体Flt-1和细胞表面上表达人VEGF受体Flt-1的细胞免疫反应的抗体或肽，以及抑制人VEGF与人VEGF受体Flt结合的抗体或肽 -1。它还提供了用于诊断或治疗其病态通过异常血管生成进行的疾病（例如实体瘤的增殖或转移，类风湿性关节炎中的关节炎，糖尿病性视网膜病，早产儿视网膜病，牛皮癣等）的手段。

12. 发明授权

US5939532A Humanized antibodies to ganglioside GM.sub.2 失效
公开(公告)号：US5939532A
公开(公告)日：1999-08-17
申请号：US483528
申请日：1995-06-07
申请人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
发明人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
IPC分类号： C07K16/18 , C07K16/46 , C12P21/08 , C07K16/00 , C12N5/00 , C12P21/06
CPC分类号： C07K16/18 , C07K16/464 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00
摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

13. 发明申请

US20060034838A1 Anti-human VEGF receptor Flt-1 monoclonal antibody 有权
公开(公告)号：US20060034838A1
公开(公告)日：2006-02-16
申请号：US11250411
申请日：2005-10-17
申请人： Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi Shibuya
发明人： Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi Shibuya
IPC分类号： A61K39/395
CPC分类号： G01N33/57407 , A61K38/00 , C07K16/2803 , C07K16/2863 , C07K2317/24 , C12N2799/026 , G01N33/6863 , G01N33/6893 , G01N33/74
摘要： The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.

14. 发明授权

US06986890B1 Anti-human VEGF receptor Flt-1 monoclonal antibody 有权
公开(公告)号：US06986890B1
公开(公告)日：2006-01-17
申请号：US09453718
申请日：1999-12-03
申请人： Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi Shibuya
发明人： Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi Shibuya
IPC分类号： A61K39/395
CPC分类号： G01N33/57407 , A61K38/00 , C07K16/2803 , C07K16/2863 , C07K2317/24 , C12N2799/026 , G01N33/6863 , G01N33/6893 , G01N33/74
摘要： The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.

15. 发明授权

US06872392B2 Humanized antibodies 失效
标题翻译：人源化抗体
公开(公告)号：US06872392B2
公开(公告)日：2005-03-29
申请号：US10195752
申请日：2002-07-16
申请人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
发明人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
IPC分类号： A61K38/00 , A61P35/00 , C07K16/18 , C07K16/46 , C12P21/04 , C12P21/08 , A61K39/395 , A61K39/40 , A61K39/42 , C07K16/00
CPC分类号： C07K16/3084 , A61K38/00 , C07K16/18 , C07K16/464 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , Y10S530/867
摘要： Chimeric human antibody expression vectors are constructed by inserting the heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured to produce a chimeric human antibody reacting with the ganglioside GM2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but show a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.
摘要翻译：通过将分离自产生与神经节苷脂GM2反应的小鼠或大鼠单克隆抗体的杂交瘤的杂交瘤分离的重链可变区编码cDNA和抗体轻链可变区编码cDNA分别插入含有人类的表达载体来构建嵌合人抗体表达载体抗体重链恒定区或人抗体轻链恒定区编码cDNA。将表达载体导入动物细胞中，培养由此获得的转化体以产生与神经节苷脂GM2反应的嵌合人抗体。与小鼠单克隆抗体相反，本发明的嵌合人抗体不会引起患者体内的抗小鼠免疫球蛋白抗体的产生，但是显示出延长的血液半衰期，并且有不利影响的频率降低，从而可以预期例如，在治疗人类癌症的功效方面优于小鼠单克隆抗体。

16. 发明授权

US06423511B1 Humanized antibodies 失效
标题翻译：人源化抗体
公开(公告)号：US06423511B1
公开(公告)日：2002-07-23
申请号：US09393385
申请日：1999-09-10
申请人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
发明人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
IPC分类号： C12P2104
CPC分类号： C07K16/3084 , A61K38/00 , C07K16/18 , C07K16/464 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , Y10S530/867
摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.
摘要翻译：通过将产生与神经节苷脂GM2反应的小鼠或大鼠单克隆抗体的杂交瘤分离的抗体重链可变区编码cDNA和抗体轻链可变区编码cDNA分别插入表达载体中构建嵌合人抗体表达载体，含有人抗体重链恒定区或人抗体轻链恒定区编码cDNA的动物细胞。将表达载体导入动物细胞，并将由此获得的转化体培养以产生与神经节苷脂GM2反应的嵌合人抗体。与小鼠单克隆抗体相反，本发明的嵌合人抗体不会导致患者体内的抗小鼠免疫球蛋白抗体产生，但显示出延长的血液半衰期，并且有不利影响的频率降低，从而可以预期例如，在治疗人类癌症的功效方面优于小鼠单克隆抗体。

17. 发明授权

US5874255A DNA encoding humanized antibodies specific for the ganglioside GM.sub.2 失效
标题翻译：编码针对神经节苷脂GM2的人源化抗体的DNA
公开(公告)号：US5874255A
公开(公告)日：1999-02-23
申请号：US438562
申请日：1995-05-10
申请人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
发明人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
IPC分类号： A61K38/00 , C07K16/18 , C07K16/46 , C12N1/21 , C12N15/13 , C12P21/08 , C12P21/04 , C07H21/04 , C12N15/00
CPC分类号： C07K16/3084 , C07K16/18 , C07K16/464 , A61K38/00 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/035 , Y10S530/867
摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2.In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.
摘要翻译：通过将产生与神经节苷脂GM2反应的小鼠或大鼠单克隆抗体的杂交瘤分离的抗体重链可变区编码cDNA和抗体轻链可变区编码cDNA分别插入表达载体中构建嵌合人抗体表达载体，含有人抗体重链恒定区或人抗体轻链恒定区编码cDNA的动物细胞。将表达载体导入动物细胞，并将由此获得的转化体培养以产生与神经节苷脂GM2反应的嵌合人抗体。与小鼠单克隆抗体相反，本发明的嵌合人抗体不会导致患者体内的抗小鼠免疫球蛋白抗体产生，但显示出延长的血液半衰期，并且有不利影响的频率降低，从而可以预期例如，在治疗人类癌症的功效方面优于小鼠单克隆抗体。

18. 发明授权

US08481039B2 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor 失效
标题翻译：能够结合肝素结合表皮生长因子样生长因子的单克隆抗体
公开(公告)号：US08481039B2
公开(公告)日：2013-07-09
申请号：US13365769
申请日：2012-02-03
申请人： Eisuke Mekada , Ryo Iwamoto , Shingo Miyamoto , Kenya Shitara , Akiko Furuya , Kazuyasu Nakamura , Kumiko Takahashi , Hiroshi Ando , Kazuhiro Masuda , Yuka Sasaki
发明人： Eisuke Mekada , Ryo Iwamoto , Shingo Miyamoto , Kenya Shitara , Akiko Furuya , Kazuyasu Nakamura , Kumiko Takahashi , Hiroshi Ando , Kazuhiro Masuda , Yuka Sasaki
IPC分类号： A61K39/395 , A61K39/00 , C12P21/08 , C07K1/00
CPC分类号： A61K39/39558 , A61K2039/505 , C07K16/22 , C07K16/30 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76
摘要： Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
摘要翻译：需要用于治疗与HB-EGF升高有关的疾病的药物。本发明提供了结合细胞膜结合的HB-EGF，膜型HB-EGF和分泌型HB-EGF的单克隆抗体或其抗体片段。

19. 发明授权

US07615215B2 Anti-human VEGF receptor Flt-1 monoclonal antibody 有权
公开(公告)号：US07615215B2
公开(公告)日：2009-11-10
申请号：US11277121
申请日：2006-03-21
申请人： Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi Shibuya
发明人： Kenya Shitara , Mikito Ito , Nobuo Hanai , Yoko Kawada , Kazuyasu Nakamura , Masabumi Shibuya
IPC分类号： A61K39/395 , C07K16/00 , C07K16/28
CPC分类号： G01N33/57407 , A61K38/00 , C07K16/2803 , C07K16/2863 , C07K2317/24 , C12N2799/026 , G01N33/6863 , G01N33/6893 , G01N33/74
摘要： The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.

20. 发明授权

US5830470A Humanized antibodies to ganglioside GM.sub.2 失效
公开(公告)号：US5830470A
公开(公告)日：1998-11-03
申请号：US116778
申请日：1993-09-07
申请人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
发明人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
IPC分类号： A61K38/00 , C07K16/18 , C07K16/46 , C12N1/21 , C12N15/13 , C12P21/08 , A61K39/395 , C07H21/04 , C12P21/04
CPC分类号： C07K16/3084 , C07K16/18 , C07K16/464 , A61K38/00 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/035 , Y10S530/867
摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式